Noble Financial Thinks Onconova Therapeutics’ Stock is Going to Recover


Noble Financial analyst Ahu Demir maintained a Buy rating on Onconova Therapeutics (ONTX) on July 25. The company’s shares opened today at $2.60, close to its 52-week low of $1.69.

According to TipRanks.com, Demir is a 2-star analyst with an average return of 1.5% and a 29.4% success rate. Demir covers the Healthcare sector, focusing on stocks such as Dyadic International, Electrocore Llc, and TherapeuticsMD.

Onconova Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.50, representing a 534.6% upside. In a report issued on July 18, Maxim Group also maintained a Buy rating on the stock with a $8 price target.

See today’s analyst top recommended stocks >>

Based on Onconova Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.6 million. In comparison, last year the company had a GAAP net loss of $4.48 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts